AVANT Immunotherapeutics, Inc.

Positive preliminary results from clinical trial of cholera vaccine reported

Published in Disease Risk Factor Week, August 28th, 2005

AVANT Immunotherapeutics, Inc., (AVAN) announced a breakthrough in the control of cholera with positive preliminary results from a phase II clinical trial of CholeraGarde in infants and children.

The researchers found the single dose, oral vaccine to be well tolerated and highly immunogenic, with 77% of children aged 9 months to 5 years generating protective immune responses. The ability to induce protective immune responses in children under age two would allow the introduction of the vaccine into the routine pediatric immunization calendar in endemic regions.

There are currently no licensed cholera vaccines indicated for use in children under age...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Disease Risk Factor Week

Source: Disease Risk Factor Week (2005-08-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry